Hinokitiol reduces matrix metalloproteinase expression by inhibiting Wnt/β-Catenin signaling in vitro and in vivo.

Jin Li,Xin-die Zhou,Kong-he Yang,Teng-di Fan,Wei-ping Chen,Li-feng Jiang,Jia-peng Bao,Li-dong Wu,Yan Xiong
DOI: https://doi.org/10.1016/j.intimp.2014.08.012
IF: 5.714
2014-01-01
International Immunopharmacology
Abstract:•Hinokitiol inhibits the IL-1β and Licl -induced expression of MMPs in chondrocytes.•The in vitro results indicate that hinokitiol could inhibit Wnt/β-catenin pathway.•We find the inhibitory effect of hinokitiol is weaker than that of Dkk-1.•The in vivo results show that hinokitiol could delay the progression of OA.•The study suggests hinokitiol could be a promising therapeutic agent for the OA.
What problem does this paper attempt to address?